Sinomenine-glycyrrhizic acid self-assembly enhanced the anti-inflammatory effect of sinomenine in the treatment of rheumatoid arthritis
Journal of Controlled Release,
Год журнала:
2025,
Номер
unknown, С. 113718 - 113718
Опубликована: Апрель 1, 2025
Язык: Английский
Design of indomethacin novel small molecule hydrogels for concomitant release and permeability increases
International Journal of Pharmaceutics,
Год журнала:
2025,
Номер
672, С. 125286 - 125286
Опубликована: Янв. 30, 2025
Язык: Английский
New Dawn in the Treatment of Rheumatoid Arthritis: Advanced Insight into Polymer Hydrogel Research
Gels,
Год журнала:
2025,
Номер
11(2), С. 136 - 136
Опубликована: Фев. 15, 2025
As
a
chronic
systemic
autoimmune
disease,
rheumatoid
arthritis
(RA)
not
only
damages
joints
and
other
organs
or
systems
throughout
the
body
but
also
torments
patients'
physical
mental
health
for
long
time,
seriously
affecting
their
quality
of
life.
According
to
incomplete
statistics
at
present,
global
prevalence
RA
is
approximately
0.5-1%,
number
patients
increasing
year
by
year.
Currently,
drug
therapies
are
usually
adopted
treatment
RA,
such
as
non-steroidal
anti-inflammatory
drugs
(NSAIDs),
disease-modifying
antirheumatic
(DMARDs),
glucocorticoids/steroids,
so
on.
However,
traditional
therapy
has
problems
half-lives,
cycles
requiring
frequent
administration,
lack
specificity,
possible
adverse
reactions
(such
gastrointestinal
side
effects,
skin
stratum
corneum
barrier
damage,
toxicity),
which
greatly
restrict
RA.
In
order
improve
limitations
drug,
physical,
surgical
treatments
large
related
studies
on
have
been
carried
out.
Among
them,
hydrogels
widely
used
in
research
due
excellent
biocompatibility,
mechanical
properties,
general
adaptability.
For
example,
can
be
injected
into
synovial
cavity
fluid
reduce
wear
between
joints,
lubricate
avoid
surface
degradation.
This
article
reviews
applications
under
different
functions
situation
carriers
through
delivery
routes
confirms
outstanding
potential
great
significance.
Язык: Английский
Native and modified β-cyclodextrins as solubility enhancers for methotrexate loaded in iota-carrageenan hydrogel
Journal of Molecular Liquids,
Год журнала:
2025,
Номер
unknown, С. 127407 - 127407
Опубликована: Март 1, 2025
Язык: Английский
NIR-activating glycyrrhizic acid/carbon nanozyme injectable polysaccharides-based hydrogels for promoting polymicrobial infected wound healing
International Journal of Biological Macromolecules,
Год журнала:
2025,
Номер
unknown, С. 142082 - 142082
Опубликована: Март 1, 2025
Язык: Английский
Recent Progress in Microenvironment‐Responsive Nanodrug Delivery Systems for the Targeted Treatment of Rheumatoid Arthritis
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology,
Год журнала:
2024,
Номер
16(6)
Опубликована: Ноя. 1, 2024
ABSTRACT
Rheumatoid
arthritis
(RA)
is
a
chronic
inflammatory
autoimmune
disease
that
often
causes
joint
pain,
swelling,
and
functional
impairments.
Drug
therapy
the
main
strategy
used
to
alleviate
symptoms
of
RA;
however,
drug
may
have
several
adverse
effects,
such
as
nausea,
vomiting,
abdominal
diarrhea,
gastric
ulcers,
intestinal
bleeding,
hypertension,
hyperglycemia,
infection,
fatigue,
indigestion.
Moreover,
long‐term
excessive
use
drugs
cause
liver
kidney
dysfunction,
well
thrombocytopenia.
Nanodrug
delivery
systems
(NDDSs)
can
deliver
therapeutics
diseased
sites
with
controlled
release
payload
in
an
abnormal
microenvironment,
which
helps
reduce
side
effects
therapeutics.
Abnormalities
decreased
pH,
increased
expression
matrix
metalloproteinases
(MMPs),
concentrations
reactive
oxygen
species
(ROS),
are
associated
progression
RA
but
also
provide
opportunity
achieve
microenvironment‐responsive
therapeutic
at
site.
Microenvironment‐responsive
NDDSs
overcome
abovementioned
disadvantages
therapy.
Herein,
we
comprehensively
review
recent
progress
development
for
treatment,
including
pH‐,
ROS‐,
MMP‐,
multiresponsive
NDDSs.
Furthermore,
pathological
microenvironment
highlighted
detail.
Язык: Английский
Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy
Pharmaceutics,
Год журнала:
2024,
Номер
16(12), С. 1593 - 1593
Опубликована: Дек. 13, 2024
Background/Objectives:
This
study
aimed
to
develop
a
novel
nanotechnological
slow-release
drug
delivery
platform
based
on
hyaluronic
acid
Microsponge
(MSP)
for
the
subcutaneous
administration
of
methotrexate
(MTX)
in
treatment
rheumatoid
arthritis
(RA).
RA
is
chronic
autoimmune
disease
characterized
by
joint
inflammation
and
damage,
while
MTX
common
disease-modifying
antirheumatic
(DMARD),
conventional
use
which
limited
adverse
effects
lack
release
control.
Methods:
MSP
were
synthesized
as
freeze-dried
powder
increase
their
stability
allow
facile
reconstitution
prior
precise
dosing.
Results:
A
highly
stable
rounded-shaped
micrometric
MSP,
an
open
porosity
inner
structure,
achieved
both
high
loading
efficiency
slow
after
injection.
Our
assays
indeed
demonstrated
characteristic
profile
consisting
very
burst
first
few
hours,
followed
sustained
over
month.
By
means
preclinical
rat
model
RA,
MTX-loaded
proved
nearly
double
therapeutic
efficacy
compared
sole
MTX,
according
steep
reduction
arthritic
score
control
groups.
The
was
replicated
twice
confirm
this
improvement
performance
safety
MSP.
Conclusions:
suggests
that
holds
significant
potential
clinical
improving
therapy
enabling
thereby
enhancing
outcomes
minimizing
side
associated
with
burst-release
administration.
Язык: Английский